**Excess mortality in a nationwide cohort of cancer patients during the initial phase of the COVID‑19 pandemic in Belgium**

Geert Silversmit, Freija Verdoodt, Nancy Van Damme, Harlinde De Schutter, Liesbet Van Eycken

**Table S1:** Observed, expected and excess number of deaths in the cancer cohort for the month April 2020, by cancer site. The last two columns give the expected excess number of deaths, based on the excess rates in the general population.

|  | **Number of deaths** | | **Excess (O-E)** | | **Expected excess\*\*** | |
| --- | --- | --- | --- | --- | --- | --- |
| **Cancer site/type** | **Observed (O)** | **Expected (E)** | **Estimate** | **95% CI** | **Estimate** | **95% CI** |
| All invasive tumours\* | 1,632 | 1,229 | 403 | [315, 492] | 435 | [418, 452] |
| Head and neck | 88 | 72 | 16 | [-5, 36] | 11 | [11, 12] |
| Oesophagus & GEJ | 52 | 34 | 18 | [3, 33] | 4 | [4, 4] |
| Colon and rectum | 247 | 216 | 31 | [-5, 66] | 85 | [82, 88] |
| Pancreas and peri-pancreas | 59 | 42 | 17 | [1, 34] | 4 | [4, 4] |
| Lung | 208 | 174 | 34 | [3, 65] | 20 | [19, 21] |
| Melanoma | 44 | 36 | 8 | [-7, 23] | 20 | [20, 21] |
| Breast (females) | 254 | 153 | 101 | [67, 136] | 76 | [72, 80] |
| Corpus uteri | 31 | 29 | 2 | [-11, 15] | 13 | [12, 13] |
| Ovarium | 24 | 21 | 3 | [-8, 13] | 3 | [3, 3] |
| Prostate | 222 | 172 | 50 | [17, 83] | 103 | [97, 109] |
| Kidney | 48 | 27 | 21 | [6, 36] | 13 | [13, 14] |
| Bladder | 103 | 65 | 38 | [16, 60] | 21 | [20, 22] |
| Haematologic malignancy | 212 | 168 | 44 | [11, 76] | 54 | [52, 57] |
| Solid Tumours\* | 1,447 | 1,084 | 363 | [280, 446] | 385 | [370, 400] |

GEJ = gastroesophageal junction

\* excluding non-melanoma skin cancers (ICD-10: C00.0-43.9, C45.0-96.9 and chronic myeloid neoplasms)

\*\* based on excess mortality in the general population in Belgium, during the same time frame.